Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
Open Access
- 15 July 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (14), 4225-4231
- https://doi.org/10.1158/1078-0432.ccr-06-0472
Abstract
Purpose: To establish monoclonal antibodies (mAb) against megakaryocyte potentiation factor (MPF) and detect MPF in the blood of patients with mesothelioma.Keywords
This publication has 27 references indexed in Scilit:
- Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian CancerClinical Cancer Research, 2006
- Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age‐cohort modelAmerican Journal of Industrial Medicine, 2005
- Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas but Not in Normal Pancreas and Chronic PancreatitisAmerican Journal of Clinical Pathology, 2005
- Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer PatientsClinical Cancer Research, 2005
- Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer PatientsThe Journal of Experimental Medicine, 2004
- MesothelinClinical Cancer Research, 2004
- Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal ChemotherapyJournal of Clinical Oncology, 2003
- Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNAPublished by Elsevier BV ,1995
- How GPI-anchored proteins turnover: or where do they go after arrival at the plasma membraneSeminars in Immunology, 1994
- Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesotheliumInternational Journal of Cancer, 1992